• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Genetics Market
    Genetics News
    Genetics Stocks
    • Genetics Market
    • Genetics News
    • Genetics Stocks
    1. Home>
    2. Life Science Investing NewsGenetics Investing>
    Loading...
    0

    What is Genomics?

    Bryan Mc Govern
    Jan. 25, 2018 03:55PM PST

    Genomics, the study of genetic information within all living beings, provides an insight into a patient’s genetics, opening the possibility to provide a more personalized medicine system.

    Scientist holding test tube, with DNA helix and hexagonal patterns in the background.

    Genomics refers to the study of genetic information in the DNA of all living beings. The insight into a patient’s genetics can open the possibility to offer a more personalized approach to medicine, providing one of the fastest growing markets in the life science sector.

    The World Health Organization separates genetics and genomics, stating genetics “scrutinizes the functioning and composition of the single gene,” whereas genomics, “addresses all genes and their inter-relationships in order to identify their combined influence on the growth and development of the organism.”


    Genome Canada, a non-profit with the intention to boost the use of genomic-based technologies, explained the study of genomics from is driving a shift from the traditional disease-oriented health-case system to a more preventative, predictive, and cost effective genomics-based system.

    In a 2014 Q&A with The Atlantic Eric Lander said he hoped for the next five or six years researchers would have a complete catalog of diseases genes. Lander is one of the leaders of the Human Genome Project, a map of all the letters in the DNA of a human being.

    “The rate of progress is just stunning. As costs continue to come down, we are entering a period where we are going to be able to get the complete catalogue of disease genes … That is not a cure for disease,” Lander said. “The next level will be seeing how these individual genetic components fit together, into circuits."

    Genomics: Potential worth in the future

    A report from Grand View research estimates that the global genomics market will be worth US$19.9 billion by 2020, as both public and private interest in the research and its possibilities grow.

    Similar markets encompassing the gene therapy one have caused wide speculation as to how applicable its technology is in the medical field and how much it’s worth. In 2015, former CEO at Illumina (NASDAQ:ILMN) Jay Flatley told Forbes the DNA sequencing market would be worth over $20 billion.

    Genomics’ possibilities aren’t isolated to the healthcare industry either. It is also helping us to develop hardier crops and healthier livestock, as well as grow more nutritious food. Plus, genomics broadens our understanding of the world’s biodiversity and enables new ways to mitigate the negative environmental impact.

    A look at a list of US-listed molecular diagnostic companies shows a downward trend when it comes to value. As with most life science propositions, time is of the essence with genetic investing and the patience to play the long game with this stocks is key.
    Biocept (NASDAQ:BIOC), Co-Diagnostics (NASDAQ:CODX) and Cancer Genetics (NASDAQ:CGIX) represent some of the largest players in this sector with significant achievements and a steady trend in their stock.

    While still not public, 23andMe is another company spearheading at-home genetic and health screening investors may be interested in. The company is the first and only genetic service which includes reports that meet standards for clinical and scientific validity.

    The at-home spit test is sent to certified labs and users have the option to participate in research for further studies, which could lead to personalized medicine. Google (NASDAQ:GOOGL) and Johnson & Johnson (NYSE:JNJ) are among prior investors to the company.

    Don’t forget to follow us @INN_LifeScience for real-time news updates.

    This is an update by Gabrielle Lakusta to an article originally published on the Investing News Network in 2016.

    Securities Disclosure: I, Gabrielle Lakusta and Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

    https://www.linkedin.com/in/bryan-mc-govern-b23495b0/
    bmcgovern@investingnews.com
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Bryan Mc Govern

    Bryan Mc Govern

    Senior Editor

    Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Genetics Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×
    Bryan Mc Govern
    Bryan Mc Govern

    Senior Editor

    Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.

    Full Bio

    Follow

    Learn about our editorial policies.